Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Allogeneic hematopoietic stem cell transplant outcomes for patients with dominant negative IKZF1/IKAROS mutations.

Kellner ES, Krupski C, Kuehn HS, Rosenzweig SD, Yoshida N, Kojima S, Boutboul D, Latour S, Barlogis V, Galambrun C, Stray-Pedersen A, Erichsen HC, Marsh RA.

J Allergy Clin Immunol. 2019 Apr 6. pii: S0091-6749(19)30481-6. doi: 10.1016/j.jaci.2019.03.025. [Epub ahead of print] No abstract available.

PMID:
30965037
2.

Hemophagocytic Lymphohistiocytosis: Clinical Presentations and Diagnosis.

Risma KA, Marsh RA.

J Allergy Clin Immunol Pract. 2019 Mar;7(3):824-832. doi: 10.1016/j.jaip.2018.11.050. Epub 2018 Dec 14.

PMID:
30557712
3.

Hypogammaglobulinemia with decreased class-switched B-cells and dysregulated T-follicular-helper cells in IPEX syndrome.

Shamriz O, Patel K, Marsh RA, Bleesing J, Joshi AY, Lucas L, Prince C, Pencheva BB, Kobrynski L, Chandrakasan S.

Clin Immunol. 2018 Dec;197:219-223. doi: 10.1016/j.clim.2018.10.005. Epub 2018 Oct 24.

PMID:
30368009
4.

Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies.

Marsh RA, Hebert KM, Keesler D, Boelens JJ, Dvorak CC, Eckrich MJ, Kapoor N, Parikh S, Eapen M.

J Allergy Clin Immunol. 2018 Dec;142(6):2004-2007. doi: 10.1016/j.jaci.2018.08.010. Epub 2018 Aug 28. No abstract available.

PMID:
30170121
5.

Correction to: Use of Genetic Testing for Primary Immunodeficiency Patients.

Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Itan Y, Kobrynski L, Paris K, Torgerson TR, Verbsky JW, Wasserman RL, Hsieh EWY, Bleesing JJ, Chou JS, Lawrence MG, Marsh RA, Rosenzweig SD, Orange JS, Abraham RS.

J Clin Immunol. 2018 May;38(4):540-541. doi: 10.1007/s10875-018-0510-2.

PMID:
29781065
6.

How i treat primary haemophagocytic lymphohistiocytosis.

Marsh RA, Haddad E.

Br J Haematol. 2018 Jul;182(2):185-199. doi: 10.1111/bjh.15274. Epub 2018 May 16. Review.

PMID:
29767843
7.

Screening for Wiskott-Aldrich syndrome by flow cytometry.

Chiang SCC, Vergamini SM, Husami A, Neumeier L, Quinn K, Ellerhorst T, Sheppard L, Gifford C, Buchbinder D, Joshi A, Ifversen M, Kleiner GI, Bussel JB, Chandrakasan S, Pesek RD, Pozos TC, Rose MJ, Scurlock AM, Zhang K, Bryceson YT, Bleesing J, Marsh RA.

J Allergy Clin Immunol. 2018 Jul;142(1):333-335.e8. doi: 10.1016/j.jaci.2018.04.017. Epub 2018 May 3. No abstract available.

PMID:
29729304
8.

Use of Genetic Testing for Primary Immunodeficiency Patients.

Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Tan Y, Kobrynski L, Paris K, Torgerson TR, Verbsky JW, Wasserman RL, Hsieh EWY, Blessing JJ, Chou JS, Lawrence MG, Marsh RA, Rosenzweig SD, Orange JS, Abraham RS.

J Clin Immunol. 2018 Apr;38(3):320-329. doi: 10.1007/s10875-018-0489-8. Epub 2018 Apr 19. Erratum in: J Clin Immunol. 2018 May 21;:.

PMID:
29675737
9.

Post-Transplant CD34+ Selected Stem Cell "Boost" for Mixed Chimerism after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Children and Young Adults with Primary Immune Deficiencies.

Chandra S, Bleesing JJ, Jordan MB, Grimley MS, Khandelwal P, Davies SM, Edwards S, Leemhuis T, Marsh RA.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1527-1529. doi: 10.1016/j.bbmt.2018.03.013. Epub 2018 Mar 16.

PMID:
29555312
10.

Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study.

Chandra S, Fukuda T, Mizuno K, Davies SM, Teusink-Cross A, Tarin R, Marsh RA, Vinks AA, Mehta PA.

J Antimicrob Chemother. 2018 Jun 1;73(6):1651-1658. doi: 10.1093/jac/dky030.

PMID:
29481593
11.

Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis.

Marsh RA.

Front Immunol. 2018 Jan 8;8:1902. doi: 10.3389/fimmu.2017.01902. eCollection 2017. Review.

12.

A First Report of Secondary Hemophagocytic Lymphohistiocytosis Associated With Papillary Thyroid Carcinoma.

Wakefield C, Mehta PA, Corathers S, Geller J, Gelfand M, Olowokure O, Marsh RA.

J Pediatr Hematol Oncol. 2018 Mar;40(2):e97-e98. doi: 10.1097/MPH.0000000000000991.

PMID:
29087969
13.

HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis.

Huang R, Hayashi Y, Yan X, Bu J, Wang J, Zhang Y, Zhou Y, Tang Y, Wu L, Xu Z, Liu X, Wang Q, Zhou J, Xiao Z, Bridges JP, Marsh RA, Zhang K, Jordan MB, Li Y, Huang G.

Haematologica. 2017 Nov;102(11):1956-1968. doi: 10.3324/haematol.2017.174979. Epub 2017 Aug 31.

14.

Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory disease.

Chirieleison SM, Marsh RA, Kumar P, Rathkey JK, Dubyak GR, Abbott DW.

J Biol Chem. 2017 Jun 9;292(23):9666-9679. doi: 10.1074/jbc.M117.781500. Epub 2017 Apr 12.

15.

Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.

Khandelwal P, Teusink-Cross A, Davies SM, Nelson AS, Dandoy CE, El-Bietar J, Marsh RA, Kumar AR, Grimley MS, Jodele S, Myers KC.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1122-1127. doi: 10.1016/j.bbmt.2017.03.029. Epub 2017 Mar 23.

16.

Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH.

Rubin TS, Zhang K, Gifford C, Lane A, Choo S, Bleesing JJ, Marsh RA.

Blood. 2017 Jun 1;129(22):2993-2999. doi: 10.1182/blood-2016-12-753830. Epub 2017 Mar 7.

17.

Incidence and Outcomes of Central Nervous System Hemophagocytic Lymphohistiocytosis Relapse after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.

Lounder DT, Khandelwal P, Chandra S, Jordan MB, Kumar AR, Grimley MS, Davies SM, Bleesing JJ, Marsh RA.

Biol Blood Marrow Transplant. 2017 May;23(5):857-860. doi: 10.1016/j.bbmt.2017.02.011. Epub 2017 Feb 17.

18.

Diagnostic dilemmas in HLH: Can T-cell phenotyping help?

Marsh RA.

Eur J Immunol. 2017 Feb;47(2):240-243. doi: 10.1002/eji.201646841.

19.

Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.

Marsh RA, Fukuda T, Emoto C, Neumeier L, Khandelwal P, Chandra S, Teusink-Cross A, Vinks AA, Mehta PA.

Biol Blood Marrow Transplant. 2017 Apr;23(4):635-641. doi: 10.1016/j.bbmt.2017.01.071. Epub 2017 Jan 12.

20.

Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience.

Marsh RA, Jordan MB, Talano JA, Nichols KE, Kumar A, Naqvi A, Vaiselbuh SR; Histiocyte Society Salvage Therapy Working Group.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26308. Epub 2016 Oct 27. Review.

PMID:
27786410
21.

A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.

Khandelwal P, Emoto C, Fukuda T, Vinks AA, Neumeier L, Dandoy CE, El-Bietar J, Chandra S, Davies SM, Bleesing JJ, Jordan MB, Mehta PA, Jodele S, Grimley MS, Kumar A, Myers KC, Marsh RA.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2220-2225. doi: 10.1016/j.bbmt.2016.09.016. Epub 2016 Sep 21.

22.

Outcome of patients with NEMO deficiency following allogeneic hematopoietic cell transplant.

Chandrakasan S, Marsh RA, Uzel G, Holland SM, Shah KN, Bleesing J.

J Allergy Clin Immunol. 2017 Mar;139(3):1040-1043.e2. doi: 10.1016/j.jaci.2016.08.039. Epub 2016 Oct 12. No abstract available.

PMID:
27744027
23.

A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.

Khandelwal P, Bleesing JJ, Davies SM, Marsh RA.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2011-2018. doi: 10.1016/j.bbmt.2016.08.013. Epub 2016 Aug 16.

24.

A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.

Khandelwal P, Fukuda T, Mizuno K, Teusink-Cross A, Mehta PA, Marsh RA, Kashuba ADM, Vinks AA, Davies SM.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1829-1835. doi: 10.1016/j.bbmt.2016.08.001. Epub 2016 Aug 3.

25.

A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.

Nelson AS, Marsh RA, Myers KC, Davies SM, Jodele S, O'Brien TA, Mehta PA.

Biol Blood Marrow Transplant. 2016 May;22(5):884-8. doi: 10.1016/j.bbmt.2016.01.026. Epub 2016 Feb 1.

26.

Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients.

Khandelwal P, Mellor-Heineke S, Rehman N, Lane A, Smiley K, Villanueva J, Marsh RA, Grimley MS, Davies SM, Filipovich AH.

Biol Blood Marrow Transplant. 2016 Apr;22(4):690-697. doi: 10.1016/j.bbmt.2015.12.016. Epub 2015 Dec 29.

27.

Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.

Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM, Filipovich AH.

Blood. 2016 Jan 28;127(4):503-12. doi: 10.1182/blood-2015-07-659672. Epub 2015 Dec 7.

28.

Accuracy of flow cytometric perforin screening for detecting patients with FHL due to PRF1 mutations.

Abdalgani M, Filipovich AH, Choo S, Zhang K, Gifford C, Villanueva J, Bleesing JJ, Marsh RA.

Blood. 2015 Oct 8;126(15):1858-60. doi: 10.1182/blood-2015-06-648659. No abstract available.

29.

Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease.

Khandelwal P, Lane A, Chaturvedi V, Owsley E, Davies SM, Marmer D, Filipovich AH, Jordan MB, Marsh RA.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1215-22. doi: 10.1016/j.bbmt.2015.04.010. Epub 2015 Apr 13.

30.

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.

Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10.

31.

Hemophagocytic lymphohistiocytosis in a female patient due to a heterozygous XIAP mutation and skewed X chromosome inactivation.

Holle JR, Marsh RA, Holdcroft AM, Davies SM, Wang L, Zhang K, Jordan MB.

Pediatr Blood Cancer. 2015 Jul;62(7):1288-90. doi: 10.1002/pbc.25483. Epub 2015 Mar 19.

PMID:
25801017
32.

Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.

Haines HL, Bleesing JJ, Davies SM, Hornung L, Jordan MB, Marsh RA, Filipovich AH.

Biol Blood Marrow Transplant. 2015 Feb;21(2):288-92. doi: 10.1016/j.bbmt.2014.10.010. Epub 2014 Oct 18.

33.

Fauna in decline--response.

Withey L, Seto K, McCauley DJ, Fiorella KJ, Marsh RA, Abrahms B, Nuñez TA, Golden CD, Brashares JS.

Science. 2014 Nov 14;346(6211):819-20. doi: 10.1126/science.346.6211.819-c. Epub 2014 Nov 13. No abstract available.

34.

Conservation policy. Wildlife decline and social conflict.

Brashares JS, Abrahms B, Fiorella KJ, Golden CD, Hojnowski CE, Marsh RA, McCauley DJ, Nuñez TA, Seto K, Withey L.

Science. 2014 Jul 25;345(6195):376-8. doi: 10.1126/science.1256734. No abstract available.

35.

Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.

Marsh RA, Bleesing JJ, Chandrakasan S, Jordan MB, Davies SM, Filipovich AH.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1641-5. doi: 10.1016/j.bbmt.2014.06.003. Epub 2014 Jun 9.

36.

Clinical flow cytometric screening of SAP and XIAP expression accurately identifies patients with SH2D1A and XIAP/BIRC4 mutations.

Gifford CE, Weingartner E, Villanueva J, Johnson J, Zhang K, Filipovich AH, Bleesing JJ, Marsh RA.

Cytometry B Clin Cytom. 2014 Jul;86(4):263-71. doi: 10.1002/cyto.b.21166. Epub 2014 Feb 19.

37.

Clinical Flow Cytometric Screening of SAP and XIAP Expression Accurately Identifies Patients with SH2D1A and XIAP/BIRC4 Mutations.

Gifford CE, Weingartner E, Villanueva J, Johnson J, Zhang K, Filipovich AH, Bleesing JJ, Marsh RA.

Cytometry B Clin Cytom. 2014 Feb 7. doi: 10.1002/cytob.21166. [Epub ahead of print]

38.

The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

Khandelwal P, Lawrence J, Filipovich AH, Davies SM, Bleesing JJ, Jordan MB, Mehta P, Jodele S, Grimley MS, Kumar A, Myers K, Marsh RA.

Pediatr Transplant. 2014 Feb;18(1):94-102. doi: 10.1111/petr.12183. Epub 2013 Oct 30.

39.

Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency.

Wada T, Kanegane H, Ohta K, Katoh F, Imamura T, Nakazawa Y, Miyashita R, Hara J, Hamamoto K, Yang X, Filipovich AH, Marsh RA, Yachie A.

Cytokine. 2014 Jan;65(1):74-8. doi: 10.1016/j.cyto.2013.09.007. Epub 2013 Sep 29.

PMID:
24084330
40.

An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.

Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, Kumar A, Jodele S, Myers KC, Chandra S, Leemhuis T, Mehta PA, Bleesing JJ, Davies SM, Jordan MB, Filipovich AH.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1625-31. doi: 10.1016/j.bbmt.2013.09.001. Epub 2013 Sep 10.

41.

Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D.

Chaigne-Delalande B, Li FY, O'Connor GM, Lukacs MJ, Jiang P, Zheng L, Shatzer A, Biancalana M, Pittaluga S, Matthews HF, Jancel TJ, Bleesing JJ, Marsh RA, Kuijpers TW, Nichols KE, Lucas CL, Nagpal S, Mehmet H, Su HC, Cohen JI, Uzel G, Lenardo MJ.

Science. 2013 Jul 12;341(6142):186-91. doi: 10.1126/science.1240094.

42.

Flow cytometric measurement of SLAM-associated protein and X-linked inhibitor of apoptosis.

Marsh RA, Bleesing JJ, Filipovich AH.

Methods Mol Biol. 2013;979:189-97. doi: 10.1007/978-1-62703-290-2_15.

PMID:
23397397
43.

Hemophagocytic Lymphohistiocytosis, Familial.

Zhang K, Filipovich AH, Johnson J, Marsh RA, Villanueva J.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2006 Mar 22 [updated 2013 Jan 17].

44.

High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients.

Myers KC, Lawrence J, Marsh RA, Davies SM, Jodele S.

Biol Blood Marrow Transplant. 2013 Mar;19(3):500-3. doi: 10.1016/j.bbmt.2012.11.011. Epub 2012 Dec 1.

45.

Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes.

Marsh RA, Rao K, Satwani P, Lehmberg K, Müller I, Li D, Kim MO, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis DA, Dimmock D, Casper J, Douglas DN, Amrolia PJ, Veys P, Kumar AR, Jordan MB, Bleesing JJ, Filipovich AH.

Blood. 2013 Feb 7;121(6):877-83. doi: 10.1182/blood-2012-06-432500. Epub 2012 Nov 6.

46.

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J, Lee ND, Khan SP, Lawrence J, Mo JQ, Bleesing JJ, Filipovich AH, Jordan MB.

Pediatr Blood Cancer. 2013 Jan;60(1):101-9. doi: 10.1002/pbc.24188. Epub 2012 Apr 22.

47.

Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome.

Shin CR, Kim MO, Li D, Bleesing JJ, Harris R, Mehta P, Jodele S, Jordan MB, Marsh RA, Davies SM, Filipovich AH.

Bone Marrow Transplant. 2012 Nov;47(11):1428-35. doi: 10.1038/bmt.2012.31. Epub 2012 Mar 19.

PMID:
22426750
48.

Familial hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease.

Marsh RA, Filipovich AH.

Ann N Y Acad Sci. 2011 Nov;1238:106-21. doi: 10.1111/j.1749-6632.2011.06265.x. Erratum in: Ann N Y Acad Sci. 2011 Dec;1246:141.

PMID:
22129058
49.

Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH.

Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, Villanueva J, Risma KA, Wei Q, Klein PS, Filipovich AH.

Blood. 2011 Nov 24;118(22):5794-8. doi: 10.1182/blood-2011-07-370148. Epub 2011 Aug 31.

50.

Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward.

Marsh RA, Jordan MB, Filipovich AH.

Br J Haematol. 2011 Sep;154(5):556-63. doi: 10.1111/j.1365-2141.2011.08785.x. Epub 2011 Jun 28. Review.

Supplemental Content

Loading ...
Support Center